and a 36-month beta value of 0.82. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SXTC is 0.56M, and at present, short sellers hold a 10.73% of that float. On November 16, 2023, the average trading volume of SXTC was 242.78K shares.
SXTC) stock’s latest price update
The stock price of China SXT Pharmaceuticals Inc (NASDAQ: SXTC) has jumped by 11.21 compared to previous close of 2.14. Despite this, the company has seen a gain of 9.18% in its stock price over the last five trading days. InvestorPlace reported 2023-08-21 that China SXT Pharmaceuticals (NASDAQ: SXTC ) stock is rocketing higher on Monday despite a lack of news from the pharmaceutical company. The Chinese pharmaceutical company hasn’t released any new news or filings that explain today’s rise.
SXTC’s Market Performance
China SXT Pharmaceuticals Inc (SXTC) has experienced a 9.18% rise in stock performance for the past week, with a -25.39% drop in the past month, and a -32.96% drop in the past quarter. The volatility ratio for the week is 17.26%, and the volatility levels for the past 30 days are at 13.65% for SXTC. The simple moving average for the past 20 days is -0.21% for SXTC’s stock, with a -57.61% simple moving average for the past 200 days.
SXTC Trading at -14.41% from the 50-Day Moving Average
After a stumble in the market that brought SXTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.29% of loss for the given period.
Volatility was left at 13.65%, however, over the last 30 days, the volatility rate increased by 17.26%, as shares sank -25.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.00% lower at present.
During the last 5 trading sessions, SXTC rose by +9.18%, which changed the moving average for the period of 200-days by -83.00% in comparison to the 20-day moving average, which settled at $2.34. In addition, China SXT Pharmaceuticals Inc saw -82.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SXTC
Current profitability levels for the company are sitting at:
- -284.40 for the present operating margin
- +21.62 for the gross margin
The net margin for China SXT Pharmaceuticals Inc stands at -301.00. The total capital return value is set at -30.38, while invested capital returns managed to touch -37.70. Equity return is now at value -38.15, with -18.81 for asset returns.
Based on China SXT Pharmaceuticals Inc (SXTC), the company’s capital structure generated 25.57 points at debt to equity in total, while total debt to capital is 20.36. Total debt to assets is 12.71, with long-term debt to equity ratio resting at 2.49. Finally, the long-term debt to capital ratio is 1.98.
When we switch over and look at the enterprise to sales, we see a ratio of -6.29, with the company’s debt to enterprise value settled at -0.32. The receivables turnover for the company is 0.57 and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.35.
To sum up, China SXT Pharmaceuticals Inc (SXTC) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.